報價延遲最少15分鐘:2025/07/17 19:38 EDT
盤後時段
|
||||
|
1.4819 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.49
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.57/-0.50
|
|
企業價值
455.20M
|
| 資產負債 |
|
每股賬面淨值
1.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 19:38 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib,a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway. |
